Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies

Table 1

P53-targeting vaccines in human cancer.

Author	Year	Study	Vaccine	Tumor site	𝑛	Disease status	Previous treatment	Imm∗	Ref
Kuball et al.	2002	Pilot study	recombinant virus	urogenital-, lung cancer, malignant schwannoma	6	advanced disease	unknown	4	[25]
Menon et al.	2003	Phase I/II	recombinant virus	colorectal cancer	16	metastatic disease	chemotherapy/radiation therapy/other	3	[26, 27]
Antonia et al.	2006	Phase I/II	recombinant virus	small cell lung cancer	29	extensive/; recurrent disease	chemotherapy (1 to ≥3 regimens)	±3	[28]
Svane et al.	2004	Phase I	peptide pulsed DC	breast cancer	6	progressive/; metastatic disease	chemotherapy/; radiotherapy/endocrine therapy	10	[29]
Svane et al.	2007	Phase II	peptide pulsed DC	breast cancer	26	progressive/; metastatic disease	chemotherapy (1–5 regimens)/endocrine treatment (1–3 regimens)	10	[30]
Lomas et al.	2004	Phase I	short peptide	breast, colorectal, non-small-cell lung, renal, prostate, head- and neck, hemangiopericytoma, esophageal cancer	14	NED/metastatic; /recurrent disease	yes	4	[31]
Rahma et al.	2010	Phase II	short peptide/peptide pulsed DC	ovarian cancer	21	NED	surgery/chemotherapy	≤31	[32–34]
Leffers et al.	2009	Phase II	long peptides	ovarian cancer	20	recurrent disease	surgery/chemotherapy	4	[35]
Speetjens et al.	2009	Phase I/II	long peptides	colorectal cancer	10	metastatic disease	surgery/chemotherapy	2	[36]

NED: no evidence of disease.∗Number of immunizations.